Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OPKO HEALTH, INC.

(OPK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OPKO HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)

06/23/2021 | 04:51pm EDT

ITEM 1.01. Entry into a Material Definitive Agreement.

On June 16, 2021, EirGen Pharma Limited ("EirGen"), an entity formed under the laws of Ireland and a subsidiary of OPKO Health, Inc., a Delaware corporation ("OPKO"), and Horizon Therapeutics Ireland DAC, an entity formed under the laws of Ireland ("Horizon"), entered into an Asset Purchase Agreement (the "Agreement"), pursuant to which EirGen agreed to sell, and Horizon agreed to purchase, all of the assets comprising EirGen's sterile fill finish facility and surrounding land in Waterford, Ireland to Horizon for $65 million in cash, less certain accrued liabilities, together with the assumption by Horizon of certain liabilities (the "Transaction"). In accordance with applicable law, certain EirGen employees will transfer to Horizon upon consummation of the Transaction. Consummation of the Transaction is subject to customary closing conditions, including the termination of a mandatory notice period to employees under applicable law. Each party's obligation to consummate the Transaction is also subject to the accuracy of the representations and warranties of the other party (subject to certain exceptions) and the performance in all material respects of the other party's respective covenants under the Agreement. The foregoing description of the Agreement is only a summary and is qualified in its entirety by reference to the complete text of the Agreement, which will be filed as an exhibit to OPKO's Quarterly Report on Form 10-Q for the period ending June 30, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about OPKO HEALTH, INC.
07/20OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
GL
07/16OPKO HEALTH, INC.(NASDAQGS : OPK) dropped from NASDAQ Biotechnology Index
CI
07/12OPKO HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
07/12OPKO HEALTH : to License Therapeutics Platform to CAMP4
MT
07/12OPKO HEALTH : Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeuti..
AQ
07/12OPKO Health, Inc. Licenses Oligonucleotide Therapeutics Platform to CAMP4 The..
CI
07/08OPKO HEALTH : to Present at the Ladenburg Thalmann Healthcare Conference
AQ
06/25OPKO HEALTH, INC. : Termination of a Material Definitive Agreement, Submission o..
AQ
06/25OPKO Health, Inc. Ratifies the Appointment of Ernst & Young LLP as the Indepe..
CI
06/25OPKO Health, Inc. Announces Election of Alice Lin-Tsing Yu, M.D., Ph.D. to th..
CI
More news
Financials (USD)
Sales 2021 1 789 M - -
Net income 2021 70,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 42,5x
Yield 2021 -
Capitalization 2 460 M 2 460 M -
Capi. / Sales 2021 1,38x
Capi. / Sales 2022 1,69x
Nbr of Employees 5 269
Free-Float 59,6%
Chart OPKO HEALTH, INC.
Duration : Period :
OPKO Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPKO HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,57 $
Average target price 8,00 $
Spread / Average Target 124%
EPS Revisions
Managers and Directors
Phillip Frost Chairman & Chief Executive Officer
Jon Roger Cohen Director & Senior Vice President
Adam E. Logal CFO, Treasurer, Chief Accounting Officer & SVP
Jane H. Hsaio Vice Chairman & Chief Technical Officer
Steven D. Rubin Director & Executive Vice President-Administration
Sector and Competitors
1st jan.Capi. (M$)
OPKO HEALTH, INC.-9.62%2 660
JOHNSON & JOHNSON9.21%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.58%218 198
ELI LILLY AND COMPANY44.05%209 276
NOVARTIS AG1.10%207 246